James Chor Sang Chim MBChB, MD, PhD, MRCP(UK), FRCP(London), FRCP(Edinburgh), FRCP(Glasgow), FACP, FRCPath(UK), FFSc(RCPA), FAcadTM, FHKAM, FHKCP

Prof Chim is the SH Ho Professor in Haematology & Oncology at the University of Hong Kong, and also an Honorary Consultant to the Department of Medicine at Queen Mary Hospital and an Honorary Oncology Specialist at the Department of Medicine and Geriatrics at Kwong Wah Hospital. Professor Chim has been awarded Fellowships of both the Royal Colleges of Physicians and also Pathologists in the United Kingdom. He has also been awarded Founding Fellowship at the Faculty of Science of the Royal College of Pathologists of Australia & the Academy of Translational Medicine of the European Society for Translational Medicine (EUSTM).

Prof Chim is a clinician scientist interested in the study of DNA methylation of tumour suppressor genes and non-coding RNAs (micro-RNAs & long noncoding RNAs) in blood cancers including multiple myeloma, lymphoma and chronic lymphocytic leukemia. So far, he has published >60 articles in the field of DNA methylation in blood cancers. Indeed, his research on “Epigenetic alterations in acute leukaemia” was awarded the prestigious State Scientific and Technological Advancement Award in China in 2009. Moreover, based on his original work in DNA methylation in blood cancer, he was awarded honorary fellowship of the Royal College of Pathologist of UK. He is also an invited member of Clinical Epigenetics Society (CLEPSO) and Cancer Epigenetics Society (CES). In this connection, he is also the associate editor of Epigenomics & Clinical Epigenetics.

Moreover, Prof Chim is an international myeloma expert. He is a member of the International Myeloma Working Group (IMWG), Executive Council Member of Asian Myeloma Network (AMN), invited founding member of International Academy of Clinical Hematology (IACH), invited member of the Global Committee of the European Society for Blood & Marrow Transplantation (EBMT), and the Chairman of the Education Program of the Asia Pacific Hematology Consortium (APHCON). Locally, he has established the Hong Kong Society of Myeloma (HKSOM), and is the Founding & current Chairman of HKSOM. He has served to formulate treatment protocols and organized clinical trials for myeloma patients in Hong Kong. Indeed, he has published & presented the clinical outcomes of myeloma patients in Hong Kong in international journals & meetings. Last but not least, Prof Chim has been helping the myeloma patients and relatives in HK to organize patient gatherings and sharing sessions. Indeed, the first patient gathering in Oct, 2015 has been published in “Myeloma Today”, a periodical of the International Myeloma Foundation, in Sep 2016, and the number of attendants expanded from ~60 in the first to ~150 in the last gathering in Oct 2016.